Lieu, Christopher H <br/><br/>
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.  [electronic resource] 

 -  The oncologist  09 2017 
 - 1024-e89 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1549-490X 
<br/><br/><label>Standard No.: </label>10.1634/theoncologist.2017-0175  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acneiform Eruptions--epidemiology<br/>Administration, Oral<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Asthenia--epidemiology<br/>Azetidines--pharmacology<br/>Colorectal Neoplasms--drug therapy<br/>Dose-Response Relationship, Drug<br/>Drug Eruptions--epidemiology<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Humans<br/>Hypokalemia--epidemiology<br/>Immunoglobulin G--pharmacology<br/>MAP Kinase Kinase 1--antagonists & inhibitors<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Piperidines--pharmacology<br/>Prospective Studies<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Receptor, ErbB-3--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Treatment Outcome